Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06191289 · ClinicalTrials.gov registry record · Phase 2
Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality
A Phase 2 study, sponsored by University of Illinois at Chicago.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT06191289: Clinical Trial Phase 2 study, sponsored by University of Illinois at Chicago.
NCT06191289 is a Phase 2 study that was terminated before completion, run by University of Illinois at Chicago. The registered enrollment target is 11 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06191289, a Phase 2 study, was terminated before completion, sponsored by University of Illinois at Chicago.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
This within-person, crossover, 2-condition, placebo-controlled study compares the impact of two perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The two conditions are (1) perimenstrual administration of estradiol and (2) natural perimenstrual withdrawal from estradiol during placebo.
Primary Outcome
Three daily survey questions assessing PSI will be administered each day (i.e., "I wished I were dead", "I wish I could go to sleep and not wake up", "I thought that life was not worth living"; scale from 1 (Not at All) to 5 (Extremely)). Composite mean scores for these 3 items are computed, providing a single number for each day, with higher daily values representing more severe PSI. Early-luteal-to-perimenstrual worsening of daily PSI is estimated for each person in each condition as the mean
Interventions
- OTHER Placebo
- DRUG Transdermal Estradiol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2024-03-16 |
| Est. Completion | 2024-12-01 |
| Phase | Phase 2 |
Why NCT06191289 stopped before completion
NCT06191289 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 11 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06191289 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06191289 about?
NCT06191289 is a clinical study titled "Neurocognitive Mechanisms of Perimenstrual Estrogen Effects on Suicidality". This within-person, crossover, 2-condition, placebo-controlled study compares the impact of two perimenstrual conditions on severity of suicidal symptoms in females with past-month suicidality but minimal risk of imminent suicide attempt. The two conditions are (1) perimenstrual administration of es...
What is the current status of trial NCT06191289?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2024-03-16. Estimated completion is 2024-12-01.
What interventions are being tested in trial NCT06191289?
The interventions under investigation include: Placebo (OTHER), Transdermal Estradiol (DRUG).
Who is sponsoring clinical trial NCT06191289?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06191289's enrollment target sits among peer trials
11 1967th of 2000 higher than 33 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03114462 · 11 participants · Phase 1
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
- NCT06039709 · 11 participants · Phase 1
Sonodynamic Therapy in Patients With Recurrent GBM
- NCT06425380 · 11 participants · NA
Pilot Open-Label Trial of Resistant Potato Starch in Patients With Cirrhosis and Overt Hepatic Encephalopathy
- NCT06472661 · 11 participants · Early Phase 1
FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI